Similar articles

• A study of the immunological effects of cimetidine in patients with lepromatous leprosy.

  Brown AE, Nelson KE, Makonkawkeyoon S, Vithayasai V, Scollard DM, Bullock WE. Brown AE, et al. Int J Lepr Other Mycobact Dis. 1985 Dec;53(4):559-64. Int J Lepr Other Mycobact Dis. 1985. PMID: 3910745 Clinical Trial.
• Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes.

  Godal T, Myklestad B, Samuel DR, Myrvang B. Godal T, et al. Clin Exp Immunol. 1971 Dec;9(6):821-31. Clin Exp Immunol. 1971. PMID: 4945738 Free PMC article.
• Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients.

  Nath I, Jayaraman J, Sathish M, Bhutani LK, Sharma AK. Nath I, et al. Clin Exp Immunol. 1984 Dec;58(3):531-8. Clin Exp Immunol. 1984. PMID: 6334579 Free PMC article.
• [Cimetidine as an immunoregulator].

  Malec P. Malec P. Postepy Hig Med Dosw. 1986 Jan-Feb;40(1):80-95. Postepy Hig Med Dosw. 1986. PMID: 2945175 Review. Polish. No abstract available.
• Suppressor cell activity and phenotypes in the blood or tissues of patients with leprosy.

  Rea TH. Rea TH. Clin Exp Immunol. 1983 Nov;54(2):298-304. Clin Exp Immunol. 1983. PMID: 6228349 Free PMC article. Review.